Concepts (142)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Self-Management | 1 | 2024 | 61 | 0.880 |
Why?
|
| Text Messaging | 2 | 2024 | 74 | 0.860 |
Why?
|
| Telemedicine | 2 | 2020 | 333 | 0.850 |
Why?
|
| Feasibility Studies | 2 | 2024 | 522 | 0.850 |
Why?
|
| Diabetes Mellitus, Type 2 | 3 | 2024 | 675 | 0.780 |
Why?
|
| Mobile Applications | 2 | 2021 | 130 | 0.770 |
Why?
|
| Patient Education as Topic | 1 | 2024 | 447 | 0.730 |
Why?
|
| Diabetes Mellitus | 3 | 2024 | 533 | 0.730 |
Why?
|
| Smoking Cessation | 3 | 2022 | 531 | 0.720 |
Why?
|
| Patient Satisfaction | 3 | 2024 | 413 | 0.660 |
Why?
|
| Electronic Health Records | 3 | 2021 | 350 | 0.620 |
Why?
|
| Self Care | 2 | 2024 | 211 | 0.610 |
Why?
|
| Internet | 3 | 2018 | 457 | 0.580 |
Why?
|
| Motivation | 1 | 2020 | 266 | 0.580 |
Why?
|
| Patient Compliance | 2 | 2016 | 371 | 0.490 |
Why?
|
| Patient Access to Records | 1 | 2014 | 4 | 0.470 |
Why?
|
| Patient Participation | 1 | 2016 | 209 | 0.450 |
Why?
|
| Substance-Related Disorders | 1 | 2020 | 689 | 0.420 |
Why?
|
| Superoxide Dismutase | 3 | 2011 | 213 | 0.420 |
Why?
|
| Neuroprotective Agents | 2 | 2010 | 73 | 0.410 |
Why?
|
| Information Seeking Behavior | 3 | 2018 | 35 | 0.390 |
Why?
|
| Amyotrophic Lateral Sclerosis | 3 | 2011 | 474 | 0.370 |
Why?
|
| Uridine | 1 | 2010 | 16 | 0.350 |
Why?
|
| Health Services Accessibility | 1 | 2015 | 542 | 0.350 |
Why?
|
| Patient Portals | 2 | 2021 | 45 | 0.310 |
Why?
|
| Diabetes Mellitus, Type 1 | 3 | 2024 | 607 | 0.260 |
Why?
|
| Humans | 19 | 2024 | 59308 | 0.230 |
Why?
|
| Self Efficacy | 1 | 2024 | 201 | 0.220 |
Why?
|
| Goals | 2 | 2021 | 89 | 0.210 |
Why?
|
| Communication | 2 | 2018 | 552 | 0.190 |
Why?
|
| Hypoglycemia | 1 | 2022 | 68 | 0.190 |
Why?
|
| Pilot Projects | 1 | 2024 | 918 | 0.190 |
Why?
|
| Health Behavior | 1 | 2024 | 473 | 0.180 |
Why?
|
| Craving | 1 | 2020 | 35 | 0.170 |
Why?
|
| Single-Blind Method | 1 | 2020 | 134 | 0.170 |
Why?
|
| Multicenter Studies as Topic | 1 | 2020 | 115 | 0.170 |
Why?
|
| Smartphone | 1 | 2020 | 61 | 0.170 |
Why?
|
| Middle Aged | 7 | 2024 | 16233 | 0.170 |
Why?
|
| Reward | 1 | 2020 | 82 | 0.170 |
Why?
|
| Male | 10 | 2024 | 27482 | 0.170 |
Why?
|
| Software Design | 1 | 2019 | 28 | 0.160 |
Why?
|
| Smokers | 1 | 2019 | 108 | 0.150 |
Why?
|
| Adaptation, Psychological | 1 | 2020 | 263 | 0.150 |
Why?
|
| Alcoholism | 1 | 2020 | 306 | 0.140 |
Why?
|
| Home Health Nursing | 1 | 2016 | 2 | 0.140 |
Why?
|
| Health Services Needs and Demand | 2 | 2015 | 214 | 0.140 |
Why?
|
| Research Design | 1 | 2020 | 565 | 0.140 |
Why?
|
| Female | 9 | 2024 | 30805 | 0.140 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2020 | 666 | 0.130 |
Why?
|
| Adult | 4 | 2024 | 15731 | 0.130 |
Why?
|
| Attitude to Health | 2 | 2018 | 275 | 0.130 |
Why?
|
| Health Promotion | 1 | 2019 | 491 | 0.120 |
Why?
|
| Patient Protection and Affordable Care Act | 1 | 2015 | 46 | 0.120 |
Why?
|
| Medical Informatics | 1 | 2015 | 68 | 0.120 |
Why?
|
| Attitude to Computers | 1 | 2014 | 21 | 0.120 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2014 | 33 | 0.120 |
Why?
|
| Health Records, Personal | 1 | 2014 | 26 | 0.120 |
Why?
|
| Patient Outcome Assessment | 1 | 2014 | 55 | 0.110 |
Why?
|
| Patient-Centered Care | 1 | 2016 | 248 | 0.110 |
Why?
|
| Anterior Horn Cells | 2 | 2010 | 6 | 0.110 |
Why?
|
| Professional-Patient Relations | 1 | 2014 | 127 | 0.110 |
Why?
|
| Veterans | 1 | 2021 | 722 | 0.110 |
Why?
|
| Cost-Benefit Analysis | 1 | 2014 | 287 | 0.100 |
Why?
|
| Rats, Sprague-Dawley | 2 | 2011 | 569 | 0.100 |
Why?
|
| Mice, Transgenic | 3 | 2010 | 1221 | 0.100 |
Why?
|
| Pyrazolones | 1 | 2011 | 1 | 0.100 |
Why?
|
| Prognosis | 1 | 2016 | 1564 | 0.100 |
Why?
|
| Body Weight | 2 | 2010 | 378 | 0.100 |
Why?
|
| Technology | 2 | 2022 | 50 | 0.090 |
Why?
|
| Pyrazoles | 1 | 2011 | 74 | 0.090 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2016 | 740 | 0.090 |
Why?
|
| Creatine Kinase, BB Form | 1 | 2010 | 1 | 0.090 |
Why?
|
| Deoxyguanosine | 1 | 2010 | 20 | 0.090 |
Why?
|
| Rats | 2 | 2011 | 1907 | 0.090 |
Why?
|
| Random Allocation | 1 | 2010 | 198 | 0.090 |
Why?
|
| Phenylbutyrates | 1 | 2009 | 5 | 0.080 |
Why?
|
| Riluzole | 1 | 2009 | 7 | 0.080 |
Why?
|
| Spinal Cord | 1 | 2010 | 195 | 0.080 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2010 | 387 | 0.080 |
Why?
|
| Behavior, Animal | 1 | 2010 | 214 | 0.080 |
Why?
|
| Huntington Disease | 1 | 2010 | 146 | 0.080 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2010 | 810 | 0.080 |
Why?
|
| Central Nervous System | 1 | 2010 | 191 | 0.080 |
Why?
|
| Survival Rate | 1 | 2010 | 787 | 0.070 |
Why?
|
| Energy Metabolism | 1 | 2010 | 348 | 0.070 |
Why?
|
| Aged | 4 | 2018 | 13288 | 0.070 |
Why?
|
| Mice, Inbred C57BL | 2 | 2010 | 3189 | 0.070 |
Why?
|
| United States | 2 | 2015 | 7490 | 0.060 |
Why?
|
| Mice | 4 | 2011 | 10256 | 0.060 |
Why?
|
| Evidence-Based Practice | 1 | 2024 | 82 | 0.060 |
Why?
|
| Disease Models, Animal | 1 | 2010 | 2062 | 0.050 |
Why?
|
| Blood Glucose Self-Monitoring | 1 | 2022 | 58 | 0.050 |
Why?
|
| Carbon Monoxide | 1 | 2022 | 59 | 0.050 |
Why?
|
| Pediatrics | 1 | 2024 | 266 | 0.050 |
Why?
|
| Cross-Sectional Studies | 2 | 2021 | 2461 | 0.050 |
Why?
|
| Animals | 4 | 2011 | 19612 | 0.040 |
Why?
|
| Superoxide Dismutase-1 | 2 | 2011 | 134 | 0.040 |
Why?
|
| Documentation | 1 | 2021 | 129 | 0.040 |
Why?
|
| Blood Glucose | 1 | 2022 | 470 | 0.040 |
Why?
|
| Georgia | 1 | 2018 | 88 | 0.040 |
Why?
|
| Consumer Health Information | 1 | 2018 | 33 | 0.040 |
Why?
|
| Delivery of Health Care | 1 | 2022 | 421 | 0.040 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2021 | 446 | 0.030 |
Why?
|
| Focus Groups | 1 | 2016 | 290 | 0.030 |
Why?
|
| Acute Coronary Syndrome | 1 | 2018 | 256 | 0.030 |
Why?
|
| Child | 1 | 2024 | 4299 | 0.030 |
Why?
|
| Physician-Patient Relations | 1 | 2018 | 386 | 0.030 |
Why?
|
| Health Personnel | 1 | 2018 | 340 | 0.030 |
Why?
|
| Choice Behavior | 1 | 2014 | 76 | 0.030 |
Why?
|
| Data Collection | 1 | 2014 | 384 | 0.030 |
Why?
|
| Massachusetts | 1 | 2018 | 2083 | 0.030 |
Why?
|
| Cytochrome P-450 Enzyme Inhibitors | 1 | 2011 | 4 | 0.020 |
Why?
|
| Microsomes, Liver | 1 | 2011 | 18 | 0.020 |
Why?
|
| ERG1 Potassium Channel | 1 | 2011 | 6 | 0.020 |
Why?
|
| Ether-A-Go-Go Potassium Channels | 1 | 2011 | 7 | 0.020 |
Why?
|
| Ethers | 1 | 2011 | 17 | 0.020 |
Why?
|
| Cell Membrane Permeability | 1 | 2011 | 39 | 0.020 |
Why?
|
| Sulfones | 1 | 2011 | 40 | 0.020 |
Why?
|
| Caco-2 Cells | 1 | 2011 | 65 | 0.020 |
Why?
|
| Solubility | 1 | 2011 | 173 | 0.020 |
Why?
|
| Blood-Brain Barrier | 1 | 2011 | 82 | 0.020 |
Why?
|
| In Vitro Techniques | 1 | 2011 | 475 | 0.020 |
Why?
|
| Drug Design | 1 | 2011 | 143 | 0.020 |
Why?
|
| Structure-Activity Relationship | 1 | 2011 | 376 | 0.020 |
Why?
|
| Postmortem Changes | 1 | 2010 | 10 | 0.020 |
Why?
|
| Mice, Inbred CBA | 1 | 2010 | 82 | 0.020 |
Why?
|
| HEK293 Cells | 1 | 2011 | 577 | 0.020 |
Why?
|
| NF-kappa B p50 Subunit | 1 | 2009 | 22 | 0.020 |
Why?
|
| Muscle Strength | 1 | 2009 | 37 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2021 | 5972 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2010 | 306 | 0.020 |
Why?
|
| Acetylation | 1 | 2009 | 111 | 0.020 |
Why?
|
| Drug Synergism | 1 | 2009 | 132 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2009 | 434 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2010 | 1059 | 0.020 |
Why?
|
| Neurons | 1 | 2011 | 858 | 0.020 |
Why?
|
| Histones | 1 | 2009 | 463 | 0.020 |
Why?
|
| Phenotype | 1 | 2009 | 1155 | 0.020 |
Why?
|
| Biomarkers | 1 | 2010 | 1205 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2014 | 5066 | 0.010 |
Why?
|
| Mutation | 1 | 2011 | 2427 | 0.010 |
Why?
|
| Adolescent | 1 | 2014 | 5915 | 0.010 |
Why?
|